Drug Portfolio.

AIkido Labs, successor to AIkido Pharma Inc. is focused on the treatment of four cancers, prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). 

AIkido Labs also has an Exclusive World-Wide License to Broad Spectrum Antiviral Drug Platform, Includes Coronavirus, from the University of Maryland Baltimore.

About AIkido Labs Inc.

AIkido Labs Inc. is a biotechnology development company working to develop a diverse portfolio of early and mid-stage small-molecule anti-cancer therapeutics. The AIkido Labs Inc. platform contains patented technology from leading universities and researchers and we seek to develop our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Our prostate and pancreatic treatment has shown positive preclinical results.